NIKKEI 225
39,699.57 +526.42 (+1.34%) HANG SENG
18,064.83 -8.07 (-0.04%) CRUDE OIL
81.20 +0.37 (+0.46%) GOLD FUTURES
2,329.30 -1.50 (-0.06%) DOW
39,112.16 -299.05 (-0.76%) Bitcoin GBP
48,802.91 +508.81 (+1.05%)
DYN Sep 2024 35.000 call
| Previous close | 3.4000 |
| Open | 3.2000 |
| Bid | 2.6500 |
| Ask | 5.3000 |
| Strike | 35.00 |
| Expiry date | 2024-09-20 |
| Day's range | 3.2000 - 3.4000 |
| Contract range | N/A |
| Volume | |
| Open interest | 881 |
GlobeNewswireDyne Therapeutics Presents New Preclinical Data Demonstrating the Potential of the FORCE™ Platform to Deliver Enzyme Replacement Therapy to Muscle and CNS in Pompe Disease
WALTHAM, Mass., June 24, 2024 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today announced new preclinical data in a Pompe disease model demonstrating the potential of the FORCE™ platform to deliver enzyme replacement therapy to cardiac and skeletal muscle and the central nervous system (CNS). The data were presented at the New D
- GlobeNewswire
Dyne Therapeutics Presents New Preclinical Data for its Facioscapulohumeral Muscular Dystrophy Program During the FSHD Society International Research Congress
- Leveraging the FORCE™ Platform, DYNE-302 Achieved Robust and Durable DUX4 Suppression and Functional Benefit in FSHD Preclinical Models - WALTHAM, Mass., June 13, 2024 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today highlighted new preclinical data for DYNE-302, its product candidate for facioscapulohumeral muscular dystroph
- GlobeNewswire
Dyne Therapeutics to Present at Jefferies Global Healthcare Conference
WALTHAM, Mass., May 30, 2024 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today announced that management is scheduled to participate in a fireside chat at the Jefferies Global Healthcare Conference in New York on Thursday, June 6, 2024 at 3:00 p.m. ET. A live webcast will be available in the Investors & Media section of Dyne’s w
